Annovis Bio Shares Surge 45% on Positive Biomarker Data and Phase 3 AD Milestone
By ATTN Desk · Editorial oversight: Sean Han
Introduction
Annovis Bio Inc (ticker: ANVS; exchange: NYS) is a clinical-stage biotechnology company developing therapies for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD). On November 17, 2025, ANVS closed at $3.4030 per share, reflecting a 45.43% increase on a volume of 19,676,101 shares. The company’s lead asset, buntanetap, is an oral small-molecule inhibitor of neurotoxic proteins in the brain.
Corporate Structure
Founded in May 2008 by Dr. Maria Maccecchini, Annovis Bio is headquartered in Malvern, Pennsylvania. It operates as a privately held entity with 2–10 employees. Key executives include:
- Maria Maccecchini, Ph.D. (Founder & CEO)
- Mark Guerin, CPA, CMA, CFM (Chief Financial Officer; appointed November 2025)
- Dr. Fang, Dr. Christie, Ms. Gaines, Ms. Damiano, and Sarah MacCallum, RN, serving in senior R&D, operations, and clinical roles.
Neurodegenerative therapies by Milad Fakurian
Recent Developments and News
- October 28, 2025: Filed a Form 8-K (items 1.01, 8.01, 9.01) disclosing material corporate events.
- November 12, 2025: Submitted Form 10-Q for the quarter ended September 30, 2025, reporting a net loss of $24.88 million (ttm) and $15.29 million in cash and equivalents.
- November 13, 2025: Filed Form 8-K (items 2.02, 9.01) with updates on corporate developments.
- November 17–18, 2025: Participated in Reuters Events Pharma Clinical Innovation USA in Philadelphia, where Dr. Maccecchini presented “Beyond Perfection: How Mistakes Shape Path to Approval.”
- Clinical Trial Milestones: All 84 U.S. sites in the pivotal Phase 3 early AD study are activated; the trial is 25% enrolled, and the first patients have completed six months of treatment.
- Biomarker Findings (November 2025): Annovis reported data indicating that buntanetap reduces inflammatory and neurodegenerative biomarkers in AD patients.
- CFO Appointment: Mark Guerin joined as CFO, bringing experience from Onconova Therapeutics and Cardiokine, Inc.
Financial and Strategic Aspects
| Metric | Value |
|---|---|
| Share Price (2025-11-17) | $3.4030 |
| Daily Change | +45.43% |
| Trading Volume | 19,676,101 shares |
| Market Capitalization | $92.1 million |
| Shares Outstanding | 26.5 million |
| Cash & Equivalents (mrq) | $15.29 million |
| Net Loss (ttm) | $24.88 million |
| Revenue (ttm) | $0 |
Annovis Bio has not yet received product approvals and relies on equity financing and grant funding to support its research and development (R&D) efforts. The balance sheet indicates a moderate cash runway that likely requires additional capital raises or partnerships. The company’s strategic focus remains on enrolling patients in the Phase 3 AD study, advancing indications for PD, and exploring applications in Down syndrome and traumatic brain injury.
Market Position and Industry Context
Annovis operates in the neurodegenerative disease treatment sector, facing competition from larger pharmaceutical and biotechnology firms targeting amyloid, tau, and synuclein pathways. Its approach of modulating multiple neurotoxic proteins with a single molecule differentiates buntanetap from monoclonal antibodies and gene therapies. Key risks include clinical trial outcomes, regulatory approval timelines, and funding needs. Success in the Phase 3 Alzheimer’s trial could position Annovis as a notable provider of an oral, disease-modifying treatment.
tl;dr
On November 17, 2025, ANVS shares increased by 45.43% to $3.4030, supported by new biomarker data and progress in Phase 3 enrollment for its early AD trial. All 84 U.S. clinical sites are active, and the first cohort has reached six months of treatment. Annovis reported a cash position of $15.3 million against an annual loss of $24.88 million. Future developments include additional Phase 3 data readouts and potential financing activities to extend the cash runway.